Synairgen
('Synairgen' or the 'Company')
Board and Executive Leadership Changes
Southampton, UK - 16 May 2025: Synairgen, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces a number of changes in the executive leadership of the company.
Mr Richard Marsden will step down from the role of Chief Executive Officer and as Company Director and Board member with effect from 1 July 2025. As part of the transition of leadership of the Company, Mr Marsden will be retained as a part-time Board Advisor to maintain continuity and to ensure his significant expertise in the field is secured for the Company.
Mr Joseph Colliver , currently Chief Financial Officer, will step up to the role of Chief Executive Officer. Mr Colliver joined Synairgen in October 2023 and has a broad professional business background with a track record in senior leadership roles, finance and fund raising, corporate transactions, and commercial partnerships.
Dr Mark Parry-Billings who joined Synairgen as Non-Executive Chairman in October 2024, will transition, also on 1 July 2025, to the role of Executive Chairman maintaining his leadership of the Board whilst leveraging his pharma and biotech R&D and business experience to further support the Company's core program.
Dr Parry-Billings added: "I would like to sincerely acknowledge Richard's very significant tenure leading Synairgen as CEO for twenty years and his material contributions to advancing the business and our programs. Joseph is a highly talented executive with the right skills to lead and drive the company to its next value-inflection. I am very much looking forward to continuing the productive working relationship with both Joseph and Richard in their new roles as we advance in the very high unmet medical need population of mechanically-ventilated patients with viral pneumonia."
For further enquiries, please contact:
| Synairgen plc |
+ 44 (0)23 8051 2800 |
| |
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
For more information about Synairgen, please see www.synairgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.